However, despite a phase 1b clinical trial combining azacitidine with the anti-CD47 antibody magrolimab demonstrated encouraging results in higher-risk MDS patients, the subsequent phase 3 clinical trial failed to show superior efficacy of the azacitidine + magrolimab combination compared to azacitidine + placebo. The gene discussed is CD47; the disease is myelodysplastic syndrome.